Eloxx Pharmaceuticals Inc. (ELOX)
$15.86
$0.85
(5.66%)
As on 02-Sep-2026 15:33EDT
Market cap
$52 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
4.3
P/B Ratio
1.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-13 Mln
-
ROE
0 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.1
-
Debt to Equity
-0.1
-
Book Value
$--
-
EPS
$-17.3
-
Face value
--
-
Shares outstanding
3,436,314
10 Years Aggregate
CFO
$-201.58 Mln
EBITDA
$-243.23 Mln
Net Profit
$-297.26 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Eloxx Pharmaceuticals (ELOX)
| -- | -- | -- | -- | 43.2 | -24.1 | -18.8 |
|
BSE Sensex
| -9.6 | -2.0 | 3.1 | -4.7 | 5.4 | 6.0 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Eloxx Pharmaceuticals (ELOX)
| -34.1 | -93.6 | -82.3 | -45.9 | -38.7 | 49.8 | 185.3 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Eloxx Pharmaceuticals (ELOX)
|
15.9 | 51.8 | 0.0 | -6.0 | -- | 33.1 | 4.3 | 1.2 |
| 84.3 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 265.6 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 71.2 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 58.4 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 109.2 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 366.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 543.3 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 592.3 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 357.4 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Eloxx Pharmaceuticals (ELOX)
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel,... and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for the treatment of rare skin diseases, such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations. Eloxx Pharmaceuticals, Inc. was incorporated in 1999 and is based in Arlington, Massachusetts. Read more
-
President, CEO & Director
Mr. Sumit Aggarwal M.B.A.
-
President, CEO & Director
Mr. Sumit Aggarwal M.B.A.
-
Headquarters
Arlington, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Eloxx Pharmaceuticals (ELOX)
What is the current share price of Eloxx Pharmaceuticals Inc (ELOX) Today?
The share price of Eloxx Pharmaceuticals Inc (ELOX) is $15.86 (NASDAQ) as of 02-Sep-2026 15:33 EDT. Eloxx Pharmaceuticals Inc (ELOX) has given a return of 43.21% in the last 3 years.
What is the current PB & PE ratio of Eloxx Pharmaceuticals Inc (ELOX)?
The P/E ratio of Eloxx Pharmaceuticals Inc (ELOX) is 4.28 times as on 28-Aug-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-- |
-- |
2024 |
-- |
-- |
2023 |
-0.02 |
-0.01 |
2022 |
-0.01 |
-0.03 |
2021 |
-0.02 |
0.07 |
What is the 52 Week High and Low of Eloxx Pharmaceuticals Inc (ELOX)?
The 52-week high and low of Eloxx Pharmaceuticals Inc (ELOX) are Rs 19.82 and Rs 13.93 as of 03-Sep-2026.
What is the market cap of Eloxx Pharmaceuticals Inc (ELOX)?
Eloxx Pharmaceuticals Inc (ELOX) has a market capitalisation of $ 52 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Eloxx Pharmaceuticals Inc (ELOX)?
Before investing in Eloxx Pharmaceuticals Inc (ELOX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.